9.70
price up icon3,157%   9.4022
after-market After Hours: 9.51 -0.19 -1.96%
loading
Cellectar Biosciences Inc stock is traded at $9.70, with a volume of 179.38K. It is up +3,157% in the last 24 hours and up +3,794% over the past month. Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
See More
Previous Close:
$0.2978
Open:
$8.55
24h Volume:
179.38K
Relative Volume:
0.02
Market Cap:
$16.86M
Revenue:
-
Net Income/Loss:
$-37.75M
P/E Ratio:
-2.9846
EPS:
-3.25
Net Cash Flow:
$-30.91M
1W Performance:
+2,660%
1M Performance:
+3,794%
6M Performance:
+3,726%
1Y Performance:
+239.16%
1-Day Range:
Value
$8.30
$9.85
1-Week Range:
Value
$0.2803
$9.85
52-Week Range:
Value
$0.224
$9.85

Cellectar Biosciences Inc Stock (CLRB) Company Profile

Name
Name
Cellectar Biosciences Inc
Name
Phone
(608) 441-8120
Name
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Name
Employee
11
Name
Twitter
@CellectarBio
Name
Next Earnings Date
2025-03-05
Name
Latest SEC Filings
Name
CLRB's Discussions on Twitter

Compare CLRB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CLRB
Cellectar Biosciences Inc
9.70 16.86M 0 -37.75M -30.91M -3.25
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.27 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
522.27 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.00 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
568.06 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
266.80 28.51B 3.81B -644.79M -669.77M -6.24

Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-05-24 Resumed Ladenburg Thalmann Buy
Jul-01-20 Initiated Oppenheimer Outperform
Jan-21-20 Resumed ROTH Capital Buy
Sep-13-19 Initiated ROTH Capital Buy
Dec-21-16 Initiated Ladenburg Thalmann Buy

Cellectar Biosciences Inc Stock (CLRB) Latest News

pulisher
Jun 18, 2025

Cellectar Biosciences announces one-for-thirty reverse stock split - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Cellectar Biosciences (CLRB) Announces One-for-Thirty Reverse St - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Cellectar Biosciences announces 1:30 reverse stock split - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Cellectar Biosciences (CLRB) Announces Reverse Stock Split | CLR - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Cellectar Biosciences Reports 1-for-30 Reverse Stock Split, Effective June 24 - marketscreener.com

Jun 18, 2025
pulisher
Jun 18, 2025

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split | CLRB Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Cellectar Biosciences, Inc. Announces One-for-Thirty Reverse Stock Split Effective June 24, 2025 - Nasdaq

Jun 18, 2025
pulisher
Jun 18, 2025

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split - GlobeNewswire

Jun 18, 2025
pulisher
Jun 16, 2025

Roth Capital Issues Positive Estimate for CLRB Earnings - Defense World

Jun 16, 2025
pulisher
Jun 13, 2025

Cellectar Biosciences Approves Reverse Stock Split Proposal - TipRanks

Jun 13, 2025
pulisher
Jun 11, 2025

Cellectar Biosciences (CLRB) Reports Promising Phase 1 Trial Res - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 - GlobeNewswire

Jun 11, 2025
pulisher
Jun 11, 2025

Cellectar reports improved survival in pediatric brain tumor trial By Investing.com - Investing.com India

Jun 11, 2025
pulisher
Jun 11, 2025

Cellectar reports improved survival in pediatric brain tumor trial - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma - The Manila Times

Jun 11, 2025
pulisher
Jun 11, 2025

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma | CLRB Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Breakthrough: New Drug Doubles Survival Time in Aggressive Childhood Brain Cancer Trial - Stock Titan

Jun 11, 2025
pulisher
Jun 09, 2025

Squarepoint Ops LLC Makes New Investment in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Cellectar Biosciences announces $2.5 million stock sale By Investing.com - Investing.com India

Jun 06, 2025
pulisher
Jun 05, 2025

Cellectar Biosciences Enters into Common Stock Agreements to Rai - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Cellectar Biosciences Expects to Raise $2.5 Million via Stock Sale, Warrant Exercise - marketscreener.com

Jun 05, 2025
pulisher
Jun 05, 2025

Cellectar Biosciences (CLRB) Secures $2.5 Million from Stock Sal - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 05, 2025

Cellectar Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow

Jun 05, 2025
pulisher
Jun 05, 2025

Cellectar Biosciences (CLRB) Secures $2.5M Through Stock Sale Agreements | CLRB Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Cellectar Biosciences announces $2.5 million stock sale - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules | CLRB Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Cellectar Biosciences Enters into Common Stock Agreements - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

FDA Designation Sparks Rally For This Biotech - The Globe and Mail

Jun 04, 2025
pulisher
Jun 04, 2025

Cellectar Biosciences stock soars on FDA breakthrough designation - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

Cellectar Biosciences stock soars on FDA breakthrough designation By Investing.com - Investing.com Canada

Jun 04, 2025
pulisher
Jun 04, 2025

Cellectar Biosciences Stock Price, Quotes and Forecasts | NASDAQ:CLRB - Benzinga

Jun 04, 2025
pulisher
Jun 04, 2025

Cellectar Biosciences (CLRB) Secures Breakthrough Therapy Designation | CLRB Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

US Stocks Higher; Dollar Tree Shares Plunge After Q1 Earnings - Benzinga

Jun 04, 2025
pulisher
Jun 04, 2025

Cellectar Granted U.S. FDA Breakthrough Therapy Designation - GlobeNewswire

Jun 04, 2025
pulisher
Jun 04, 2025

Cellectar Biosciences Says FDA Granted Breakthrough Therapy Designation for Experimental Cancer Drug; Shares Rise Pre-Bell - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Cellectar Biosciences (CLRB) Gains FDA Breakthrough Therapy Desi - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Cellectar Biosciences Announces Breakthrough Therapy Designation for iopofosine I 131, Reports 83.6% Overall Response Rate from CLOVER WaM Phase 2 Study - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM) - Quantisnow

Jun 04, 2025
pulisher
May 22, 2025

Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies - Yahoo Finance

May 22, 2025
pulisher
May 21, 2025

CVM Stock Offering Priced Below Previous Closing Value | CVM Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Cellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com - Defense World

May 21, 2025
pulisher
May 17, 2025

Cellectar signals Q3 EMA decision for conditional iopofosine approval while advancing pipeline and exploring strategic alternatives - MSN

May 17, 2025
pulisher
May 17, 2025

Analysts Update Their Estimates For Cellectar Biosciences Inc - Stocksregister

May 17, 2025
pulisher
May 17, 2025

Cellectar Biosciences’ (CLRB) “Hold” Rating Reiterated at Maxim Group - Defense World

May 17, 2025
pulisher
May 17, 2025

Roth Capital Brokers Increase Earnings Estimates for CLRB - Defense World

May 17, 2025
pulisher
May 15, 2025

Cellectar Biosciences Earnings Call: Progress Amid Challenges - TipRanks

May 15, 2025
pulisher
May 15, 2025

Cellectar Biosciences (CLRB) Downgraded to 'Hold' by Maxim Group - GuruFocus

May 15, 2025
pulisher
May 15, 2025

StockNews.com Initiates Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World

May 15, 2025

Cellectar Biosciences Inc Stock (CLRB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.74
price up icon 0.29%
$36.14
price up icon 2.09%
$20.92
price up icon 2.60%
$105.90
price up icon 0.46%
$105.09
price up icon 2.02%
biotechnology ONC
$266.80
price up icon 3.61%
Cap:     |  Volume (24h):